MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

Search

Organon & Co

Closed

SectorHealthcare

10.15 1.3

Overview

Share price change

24h

Current

Min

9.92

Max

10.28

Key metrics

By Trading Economics

Income

-22M

87M

Sales

-79M

1.5B

P/E

Sector Avg

3.361

40.527

EPS

1.02

Dividend yield

0.83

Profit margin

5.75

Employees

10,000

EBITDA

-13M

325M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+44.63% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.83%

2.40%

Next Earnings

5 Aug 2025

Next Dividend date

11 Sept 2025

Next Ex Dividend date

15 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-1.6B

2.5B

Previous open

8.85

Previous close

10.15

News Sentiment

By Acuity

90%

10%

368 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Organon & Co Chart

Past performance is not a reliable indicator of future results.

Related News

2 Jul 2025, 17:03 UTC

Major Market Movers

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2 Jul 2025, 15:18 UTC

Major Market Movers

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2 Jul 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Jul 2025, 23:45 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2 Jul 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2 Jul 2025, 21:01 UTC

Acquisitions, Mergers, Takeovers

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2 Jul 2025, 21:01 UTC

Acquisitions, Mergers, Takeovers

AT&T and TPG Close DIRECTV Transaction

2 Jul 2025, 20:26 UTC

Earnings

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2 Jul 2025, 20:22 UTC

Market Talk

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2 Jul 2025, 20:13 UTC

Market Talk

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2 Jul 2025, 19:09 UTC

Market Talk

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2 Jul 2025, 19:08 UTC

Market Talk

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2 Jul 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2 Jul 2025, 18:08 UTC

Market Talk

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2 Jul 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2 Jul 2025, 17:05 UTC

Acquisitions, Mergers, Takeovers

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2 Jul 2025, 17:04 UTC

Acquisitions, Mergers, Takeovers

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2 Jul 2025, 17:04 UTC

Acquisitions, Mergers, Takeovers

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2 Jul 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2 Jul 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2 Jul 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2 Jul 2025, 16:20 UTC

Market Talk

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

2 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

2 Jul 2025, 16:11 UTC

Market Talk

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2 Jul 2025, 16:09 UTC

Market Talk

Gold Futures Rise, Recouping Some Losses -- Market Talk

2 Jul 2025, 15:59 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2 Jul 2025, 15:17 UTC

Market Talk

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2 Jul 2025, 15:08 UTC

Market Talk

Luxury Sector Should Report a Slowdown -- Market Talk

2 Jul 2025, 15:00 UTC

Acquisitions, Mergers, Takeovers

Glencore: Merger of Viterra With Bunge Global Closed

Peer Comparison

Price change

Organon & Co Forecast

Price Target

By TipRanks

44.63% upside

12 Months Forecast

Average 14 USD  44.63%

High 18 USD

Low 10 USD

Based on 7 Wall Street analysts offering 12 month price targets forOrganon & Co - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

7 ratings

2

Buy

3

Hold

2

Sell

Technical Score

By Trading Central

8.53 / 9.18Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

368 / 380 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.